{Reference Type}: Journal Article
{Title}: Characteristics of psychiatric patients with hypokalemia after yokukansan administration: A retrospective study.
{Author}: Yasuda K;Takeda R;Ikeda R;Ishida Y;
{Journal}: PCN Rep
{Volume}: 2
{Issue}: 1
{Year}: 2023 Mar
暂无{DOI}: 10.1002/pcn5.76
{Abstract}: <B>UNASSIGNED: </B>Yokukansan is a Japanese herbal medicine used in psychiatry to treat behavioral and psychological symptoms of dementia and other psychiatric symptoms. However, the glycyrrhizic acid included in this medicine can cause pseudoaldosteronism and hypokalemia. We aimed to identify the risk factors for hypokalemia due to yokukansan.<BR><B>UNASSIGNED: </B>A retrospective cohort study was conducted on patients previously treated with yokukansan. The risk factors were determined by comparing the hypokalemia group with the non-hypokalemia group for each parameter.<BR><B>UNASSIGNED: </B>This study included 304 patients who received yokukansan treatment between April 2009 and March 2019. We found that 17.4% (n = 53) of the patients experienced yokukansan-induced hypokalemia. Risk factors detected as significantly different between patients with and without yokukansan-associated hypokalemia were low serum potassium concentration before yokukansan administration, dose 7.5 g /day or more, and dementia. Hypokalemia occurred earlier in patients with low albumin, low potassium, and dementia.<BR><B>UNASSIGNED: </B>It is necessary to pay attention to hypokalemia onset when administering yokukansan at 7.5 g or more to patients with low potassium levels and dementia. Our findings suggest that potassium levels must be checked early after yokukansan administration, especially in patients with low albumin, low potassium, and dementia.